Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Research Paper | Synapse

May 23, 2024Open Access

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

Key Points

Key points are not available for this paper at this time.

Abstract

In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Taskén et al. (Thu,) studied this question.

synapsesocial.com/papers/68e68ab2b6db643587612a71 https://doi.org/https://doi.org/10.2340/1651-226x.2024.34791

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients2019 · 37 citations
2A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)2018 · 782 citations
3Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study2018 · 179 citations
4The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology2023 · 31 citations